BSD Medical approvals
This article was originally published in The Gray Sheet
Executive Summary
Firm will submit PMA in 2004 for BSD-2000 deep cancer hyperthermia treatment system currently undergoing IDE clinicals for treatment of multiple cancers, including those in the pelvic region. Upgraded versions of the firm's BSD-500 systems received approval Oct. 10 to supplement an initial PMA approval for superficial and interstitial treatment of near-surface cancers. Priced at $175,000-$250,000, the new models' touch-screen displays allows better control and operation, according to the firm. BSD primarily will market the BSD-500 as a complement to installed interstitial brachytherapy systems...
You may also be interested in...
BSD Medical stock listing
BSD-2000 deep cancer hyperthermia treatment system manufacturer's application for listing on the American Stock Exchange earns approval, Salt Lake City, Utah firm states May 3 (1"The Gray Sheet" Oct. 20, 2003, In Brief). BSD, which currently trades on the OTC Bulletin Board under the symbol "BSDM," expects to begin trading on the exchange in "next several days"...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.